We are focused on bringing innovation to the treatment of cachexia and other muscle wasting conditions with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
NEWS
May 20, 2025
Actimed Therapeutics Announces New Programme to Investigate Potential Muscle Preservation Effects of S-pindolol Benzoate in Obese Patients Treated with GLP-1 Agonists
Apr 24, 2025
Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer